The FDA has rejected the drug/device combination designed to monitor patient adherence with Abilify from Otsuka Pharmaceutical and Proteus Digital Health. Just last week the FDA issued an additional warning that Abilify (aripiprazole), an atypical antipsychotic, could lead to compulsive and dangerous behaviors.
Enjoyed what you just read? Consider a donation to help us continue to produce content, provide up-to-date research news, offer continuing education courses, and continue building a community for exploring alternatives to the current paradigm of mental health. All donations are tax deductible.